MDT

83.44

+0.41%↑

VEEV

239.79

+0.81%↑

A

108.57

+1.01%↑

WBA

11.15

+0.9%↑

CHE

567.02

-1.63%↓

MDT

83.44

+0.41%↑

VEEV

239.79

+0.81%↑

A

108.57

+1.01%↑

WBA

11.15

+0.9%↑

CHE

567.02

-1.63%↓

MDT

83.44

+0.41%↑

VEEV

239.79

+0.81%↑

A

108.57

+1.01%↑

WBA

11.15

+0.9%↑

CHE

567.02

-1.63%↓

MDT

83.44

+0.41%↑

VEEV

239.79

+0.81%↑

A

108.57

+1.01%↑

WBA

11.15

+0.9%↑

CHE

567.02

-1.63%↓

MDT

83.44

+0.41%↑

VEEV

239.79

+0.81%↑

A

108.57

+1.01%↑

WBA

11.15

+0.9%↑

CHE

567.02

-1.63%↓

Search

Chimerix Inc

Lezárt

SzektorEgészségügy

8.54 0.12

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

8.54

Maximum

8.54

Chimerix Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Társak összehasonlítása

Árváltozás

Chimerix Inc Előrejelzés

Rólunk Chimerix Inc

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.